Poor solubility and low bioavailability of active pharmaceutical ingredients (APIs) have become major challenges in drug development. With a majority of new chemical entities falling under the BCS class II or IV categories, there is an increasing need for effective strategies to improve their solubility and enhance their bioavailability. In this webinar, our drug product formulation expert Giulia Milanesi will discuss the latest formulation approaches for improving the solubility and dissolution rate of poorly water-soluble compounds.
The webinar will cover various techniques and formulation types, including amorphous solid dispersion via spray drying, nanosuspensions, and lipid formulations. The first technique involves converting the crystalline structure of APIs into a more soluble amorphous form, stabilized by polymers. With nanosuspension formulations, focus is placed on reduction of the particle size of the API, and thereby increasing its surface area and dissolution rate. Lastly, lipid formulations act as carriers of the API, preventing precipitation of the solubilized compound and enhancing its absorption.
By attending this webinar, participants will gain a deeper understanding of the challenges associated with solubility and bioavailability of poorly water-soluble drugs. They will also learn about the latest formulation strategies for improving drug efficacy and bioavailability, including case studies of successful implementation. This webinar will be of interest to scientists and researchers involved in drug development and formulation, as well as professionals in the pharmaceutical industry looking to improve the performance of poorly soluble compounds.
Drug Product Formulation Development and Production
Graduated in Industrial Pharmacy with an additional specialization master in pre-formulation and pharmaceutical development, she started her career in Italy as a Formulation Scientist and later she joined Ardena in Belgium. She grew to Senior Formulation Scientist and she currently holds the position of Group Leader Formulation and Production. Her role is to support the formulation development for new chemical entities to enter the clinical studies. Her expertise is mainly focused on oral solid dosage forms such as capsules and tablets, but also nanosuspensions, lipid formulations, oral solutions, injectable formulations and solubility enhancing technologies.